Back to top

Image: Bigstock

ProQR Therapeutics N.V. (PRQR) is Overbought: Is A Drop Coming?

Read MoreHide Full Article

ProQR Therapeutics N.V. (PRQR - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because PRQR is now in overbought territory with an RSI value of 80.79.

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet PRQR’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in ProQR Therapeutics N.V’s stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of PRQR’s prospects for the near term.

Over the past two months, investors have witnessed 1 earnings estimate revisions lower compared to none higher for the current year. The consensus estimate for PRQR has also been on a downward trend over the same time period too, as the estimate has fallen from -$1.82/share two months ago to just -$1.91/share today.

If this wasn’t enough, ProQR Therapeutics N.V. also has a Zacks Rank #4 (Sell) which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ProQR Therapeutics N.V. (PRQR) - free report >>

Published in